Status
Conditions
About
According to the survey of the World Health Organization, the number of patients with depression in the world has reached 350 million, has becoming the primary cause of disability and the main disease burden worldwide. In order to better dealing with adverse reactions, improving the doctor-patient relationship and optimizing the treatment cost, FIBSER, STAR-P and HEA Health Economics Follow-up Evaluation Scale are selected as simple and quick evaluation scales to evaluate the influence, doctor-patient relationship and social and economic benefits after drug treatment in clinical treatment. At present, the reliability and validity of FIBSER, STAR-P and HEA scales will be verified the reliability and validity of the above three scales in depressive disorder, aiming at enriching the treatment of depressive patients based on assessment, thus improving the compliance of medication for depressive disorder, improving the doctor-patient relationship and reducing the total burden of social diseases.
Full description
In this study, the reliability and validity of FIBSER Scale, Doctor-patient Relationship Scale-Patient Edition (STAR-P) and HEA in Chinese population will be verified to increase the diversity and selectivity of domestic assessment tools.
This study includes two steps.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Case group:
Control group:
1)did not meet the diagnostic criteria of any axis I in DSM-5. 2)18-65 years old, with junior high school education or above. 3)Willing to participate in this study, and the subjects signed the informed consent form.
Exclusion criteria
3)serious negative suicide concept.
Loading...
Central trial contact
Yousong Su, Master; Jun Chen, M.D., Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal